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CHLOROTHIAZIDE (DIURIL) - A NEW NON-MERCURIAL 
ORAL DIURETIC 
JOHN W . KEYES, M.D.* 
FR.\NZ J. BERLACHER. M.D.* 
Clinical observation concerning a new non-mercurial oral diuretic designated by 
the generic name — chlorothiazide' constitutes this report. It is designated chemically 
as 6 - chloro. 7- sulfamyl. I . 2. 4 - benzothiadiazine - 1. 1-dioxide. 
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H2NO2S-
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It is not primarily a carbonic anhydrase inhibitor^ but seems to possess the factor 
of exerting considerable influence on the renal tubular transport of electrolytes, causing 
a marked decrease in the reabsorption ot sodium and chloride, and to a lesser degree 
poLissium and bicarbonate.''^-' The loss of sodium is apparently equal mole for 
mole to that of chloride.' In large doses it is reported' that bicarbonate is lost in 
"appreciable" amounts though never to the point of metabolic acidosis as is the case 
with carbonic anhydrase inhibitors. Smaller but effective diuretic doses produce only 
relatively minor loss of bicarbonate. 
The drug is rapidly and well absorbed by the oral loute with onset of action 
NMihin two hours and a duration of action of somewhat less than 12 hours.'* The 
pattern of electrolyte excretion with its marked chloruretic effect and rapid onset 
suggested a similarity to mercurial diuretics, and further that pretreatment with 
ammonium chloride might enhance its effect and protect the patient from hypo-
chloremic alkalosis. 
Chlorothiazide was employed in several different groups of patients. All weie 
kept on one gram sodium chloride diets and all but two were fully digitalized. All 
other diuretic agents were stopped except lor ammonium chloride. There was ;i 
total of 39 patients in the study, all in congestive failure at the time of drug 
administration. 
GROUP I : Patients seen for the first time in congestive failure in whom chloro-
thiazide was administered in lieu of a mercurial diuretic. 
•Adult Cardiology Division, Department of Medicine. 
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GROUP I I : Patients in chronic congestive heart failure who required only 
sporadic mercurial injections or were taking regular oral mercurial or non-mercurial 
diuretics. 
GROUP I I I : Patients in chronic congestive heart failure who required regular 
mercurial injections. 
GROUP IV: Patients in refractory state of congestive heart failure in whom 
regular mercurials did not produce satisfactory diuresis. 
Since chlorothiazide was reported''* to cause a marked chlorurcsis, several patients 
were followed by checking serum electrolyte disturbances. As the study progressed, 
routine determinations appeared unnecessary since apparent protection against hypo-
chloremia could be provided simply by ammonium chloride administration. The latter 
was given in one gram doses, four times daily, 3-4 consecutive days a week, as with 
the mercurial diuretics. The substitution of enteric coated potassium chloride for 
ammonium chloride, one gram three times daily for three days, may more completely 
protect Ihe patients from chloride and potassium loss. Chlorothiazide was administered 
in divided doses ranging from 250 to 1,500 mgms. per 24 hours, 3-7 days a week. 
The average dose for long-term therapy was found to be 250 mgms. three times 
ilaily at roughly six hour intervals. It appeared that a greater diuretic response was 
obtained by giving chlorothiazide on a divided dosage schedule, 2-3 times a day than 
by a single large dose in the morning, and over 3-4 consecutive days each week. 
Individual dosage adjustment was. of course, necessary since all patients did not 
respontl m a similar manner, some requiring as much as 1,500 mgms. per day, and 
others as little as 250 mgms. one day a week. The usual initial dose was 250 mgms. 
t.i.d., 3-4 consecutive days a week and ammonium chloride 4-6 grams per day the 
remaining days of the week. Larger doses gave no greater diuresis than smaller 
eltective closes. Subsequent dosage was determined by diuretic response and further 
need of therapy. Ihere was no evidence of loss of effectiveness of chlorothiazide in 
Ihe presence of ammonium chloride acidosis, as has been claimed by Maren' to be 
the case with the carbonic anhydrase inhibitor, acetazolamide. 
The iinset of diuresis was more gradual than with a parenteral mercurial, but 
continued in a more sustained and less vigorous manner, so that practically all 
piiients agreed it did not cause them the same degree of muscular discomfort and 
m.irked frequency of urination with the consequent frequent loss of sleep seen with 
Ihe shorter and more violent action of a parenteral mercurial. 
RESULTS OF STUDY 
GROUP I : Patients seen for the first time in congestive failure in whom chloro-
thiazide was administered in lieu of a mercurial diuretic. 
6 cases: 3 arteriosclerotic heart disease — 2 hypertensive cardiovascular 
disease — and 1 rheumatic heart disease. 
.Average dosage — 250 mgms. t.i.d. for 3 days. 
33 
Chlorothiazide — Oral Diuretic 
Average weight loss — 6 pounds at the end of a 3 day period. 
GROUP 11: Patients in chronic congestive heart failure who required only occasional 
mercurial injections; or were taking oral mercurial or non-mercurial 
diuretics. 
10 cases: 6 arteriosclerotic heart disease — 3 hypertensive cardiovas-
cular disease — and 10 rheumatic heart disease. 
Duration of time folloyved — 6 weeks to 4 months. 
Average time — 2'/2 months. 
Average dosage — 250 mgms. t.i.d. 3 consecutive days each yveek to 
500 mgms. t.i.d. 3 consecutive days each week. 
One case received as little as 125-250 mgms. one day a week. 
Average weight loss — 5 pounds. 
Usual loss — 3 pounds to 8 pounds at the end of each course. 
CONLMENT: No case failed to be controlled as well as with mercurials (oral and 
parenteral) or with oral non-mercurial combinations with mercurials. 
3 cases much improved over mercurial program. 
2 cases receiving regular non-mercurial oral diuretics and occasional 
mercaptomerin promptly lost 5-8 pounds when placed on chlorothiazide. 
1 case on an oral mercurial lost 5 pounds in 4 days alter use of 
chlorothiazide. 
GROUP I I I : Patients in chronic congestive heart failure who required regular 
mercurial injections. 
10 cases: 4 arteriosclerotic heart disease — 1 hypertensive cardiovas-
cular disease — and 5 rheumatic heart disease. 
Time followed — 8 to 20 weeks. 
Average dosage — 250 mgms. t.i.d. 3 consecutive days each week, to 
500 mgms. b.d. or t.i.d. 
Prior diuretic — Mercaptomerin or combinations of with chlormerodrin 
or non-mercurial oral diuretics. Average frequency of parenteral mercury 
was every 7 to 14 days. 
After chlorothiazide — average weight loss — 6 pounds; one case — 
12 pounds less. 
COMMENT: No case a failure. Every case as well controlled and a great deal more 
smoothly than on previous diuretic schedule. 
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GROUP l \ ' : Patients in refractory state ot congestive failure in whom regular 
mercurials did not produce satisfactory results. 
3 cases: all arteriosclerotic heart disease. 
.All were unimproved on mercurial program. 
All were unimproved on chlorothiazide. 
I case unimproved then did better when returned to mercurials. 
TYPICAL CASE REPORTS 
GROUP I : N.G. — 50 year old male was admitted to the Henry Ford Hospital 
in congestive failure from arteriosclerotic and hypertensive heart disease. He had been 
on digitoxin 0.2 mgms. q.d. and on a low salt diet. After admission with no change 
in therapy, his weight remained stable for three days. On the morning of the fourth 
day. he was begun on 500 mgms. chlorothiazide, b.i.d. Al the end of two days he 
had lost 7 pounds in weight and all signs of congestive heart failure had cleared except 
tor questionable minimal hepatic enlargement. He was continued on chlorothiazide 
for three more days with the further loss of one pound in weight. Serum sodium, 
potassium, chloride and carbon dioxide were drawn at this time and all were within 
normal limits. He was then given 2 cc. of parenteral mercurial to see if any further 
iliuresis could he obtained. There was no change in weight or physical findings. 
He was iliseharged to the Out-Patient Department on maintenance digitoxin and 
a one gram salt diet, and followed at about monthly intervals requiring parenteral 
mercurials. Alter three months he again was given chlorothiazide, 250 mgms. t.i.d., 
three da\s a we.k, and ammonium chloride, 1 gram q.i.d. the other four days of the 
week. Within 4S hours ot institution of chlorothiazide therapy, he lost four pounds 
in weight and his failure cleared. He has remained out of failure on this program for 
three months and has required no subsequent mercurials. 
GROl P I I : B.Z. — 44 year old female with rheumatic heart disease, auricular 
fibrillation and chronic congestive failure. She had been on digitoxin, ammonium 
chloride, one gram salt diet, chlormerodrin five days a week and occasionally required 
,1 jl.I [ enteral mercurial. She w ;is begun on chlorothiazide, 250 mgms. t.i.d., three days 
a week with 4 grams ammonium chloride the other four days of the week. On this 
program she lost 5 pounds in weight within four days with relief of symptoms and 
h.is maintained her improvement for over two months with no need for chlormerodrin 
or any parenteral mercurial. 
GROL'P HI: H G. — 70 year old female has been followed at the Henry Ford 
Hospital for many years with hypertensive cardiovascular disease, auricular fibrillation 
and chronic congestive failure. She had been on gitalin 0.5 mgms. q.d., one gram 
salt diet, raudixin, 100 mgms. b.i.d. and for many months had required parenteral 
mercurials every 7-10 da\s with intermittent ammonium chloride. Even on this program 
she had periodic congestive failure with orthopnea and paroxysmal nocturnal dy.spnea 
and edema, usualK beginning a few days prior to each mercurial injection. She was 
begun on chlorothiazide, 250 mgms. t.i.d.. 3 days a week and ammonium chloride 
the other four da\s of the week. 
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On this program, she has not needed any mercurial diuretic for five months, 
and has had no orthopnea, paroxysmal nocturnal dyspnea or edema for the first time 
in 2-3 years. 
GROUP IV: H.F. — 65 year old male with chronic, severe, intractable congestive 
fa lure and auricular ribrillation on an arteriosclerotic basis. He has been on digoxin 
0.625 mgms. q.d., one gram salt diet, intermittent ammonium chloride and parenteral 
mercurials, and in the past on chlormerodrin and acetazolamide therapy. He had 
not been well controlled on any of these programs. Recently he had become almost 
completely resistant to even parenteral mercurials. He was begun on 500 mgms. 
chlorothiazide b.i.d., 3 days a week with intermittent ammonium chloride without 
response. Dosage was increased finally to 500 mgms. t.i.d. every day but still with 
no satisfactory response. To this program was added parenteral mercurials, 2 cc. every 
3-7 days, but with only minimal improvement — that is, a weight loss of from 3-4 
pounds with each injection. However, he would regain this weight within 24 to 72 
hours. In summary, it was felt that chlorothiazide was of no significant benefit to 
this patient. 
TOXICITY: 
•Studies to date indicate chlorothiazide has little or no toxicity, however, as with all 
new drugs, alertness for signs of toxicity must be maintained. Its greatest potential 
danger seems to be the possibility of producing hypochloremia, hypokalemia or low 
sodium syndromes, exactly as with mercurials. 
Patients with kidney disease should be watched closely and possibly also those 
with liver function impairment. The drug is apparently primarily excreted by the 
kidney, being eliminated completely within 24 to 48 hours.'* However, in nephrec-
tomized dogs given chlorothiazide, considerable quantities could be recovered from 
the biliary tract.' 
Nausea or vomiting did not occur in any of our patients, the drug being exceedingly 
well tolerated. No neurologic symptoms such as headache, paresthesias, peripheral 
neuritis, etc. were found. Skin eruptions were not encountered; hemorrhagic and 
renal disturbances were checked for, but not present, and are reported absent.'-* In 
short, no evidence of toxicity was uncovered in any of the patients treated in this series. 
COMMENTS: 
Chlorothiazide appears to represent a significant advance in the diuretic manage-
ment of congestive heart failure, approaching the effectiveness of parenterally ad-
ministered mercurials, its decided advantages being: 
1) . Effective oral administration. 
2) . Apparent lack of toxicity. 
3) . Lesser potassium and bicarbonate loss than with carbonic anhydrase inhibitors. 
and therefore not as likelv to produce metabolic acidosis or hypokalemia 
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4) . Sustained diuretic action over prolonged periods (months) without apparent 
development of tolerance to the drug and without necessity of increasing 
dosage, and theretore, more even control of failure than seen with inter-
mittent parenterally administered mercurials. 
5) . Fairly rapid onset and peak of action. 
It should be stated as advisable to respect the potential danger of the drug as 
with mercurials, in giving it to patients who are salt depleted, and to be cautious in 
iismg it without the replacement of chlorides by means of ammonium chloride where 
the latter can be safely administered. 
Study is being given to the possibility of allowing less stringent dietary sodium 
chloride restriction in patients with congestive failure while being given chlorothiazide, 
since its rapid saluretic action mav prevent the accumulation of fluid. 
SUMMARY AND CONCLUSIONS: 
Chlorothiazide (6-chloro-7-sulfamyl-l ,2,4-benzothiadiozide - I , 1-dioxide) was 
toimd to be an extremely effective oral non-mercurial diuretic agent resembling most 
closely pharmacologically, the mercurial diuretics, particularly in regard to the elimina-
tion ot sodium and chloride and to a lesser increase, the excretion of potassium and 
bicarbonate. 
Therapeutic dosage varied from 250 to 1,500 mgms. per day with apparent 
increasCil elteciiveness on a divided dosage schedule. Usual maintenance dose was 
501) to I.OOO mgms. three to four consecutive days of the week, alternating with 
..mmonium chloride lor its possible potentiating and antihypochloremic effect. 
Its ellectiveness w,is not diminished with constant administration, even over a 
|ieriod ol several months. Chlorothiazide was found to be an effective replacement 
for regular oral or parenteral mercurial therapy, and resulted in a smoother control 
ol lailure than that seen with intermittent parenteral mercurials in the majority of cases. 
Effeclivc for short term diuretic action also ( 1 to 3 days). 
In our limited experience it was of no value in intractable, mercurial resistant cases. 
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